Bmi1 marks intermediate precursors during differentiation of human brain tumor initiating cells  by Venugopal, Chitra et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ loca te / sc r
Stem Cell Research (2012) 8, 141–153Bmi1 marks intermediate precursors during
differentiation of human brain tumor initiating cells
Chitra Venugopal a, 1, Na Li a, 1, Xin Wang a, Branavan Manoranjan a,
Cynthia Hawkins f, Thorsteinn Gunnarsson b, Robert Hollenberg b,
Paula Klurfan b, Naresh Murty b, Jacek Kwiecien d, Forough Farrokhyar c, g,
John P. Provias d, Christopher Wynder a, Sheila K. Singh a, b, c, e,⁎a McMaster Stem Cell and Cancer Research Institute, 1280 Main Street West, Hamilton, ON, Canada L8S 4K1
b Department of Surgery, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5
c Department of Biochemistry and Biomedical Sciences, 1200 Main Street West, Hamilton, ON Canada L8N 3Z5
d Department of Pathology and Molecular Medicine, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5
e Department of Neuroscience, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5
f Arthur and Sonia Labatt Brain Tumor Research Centre and Department of Pediatric Laboratory Medicine,
The Hospital for Sick Children and University of Toronto, ON, Canada
g Department of Health Research Methodology, Faculty of Health Sciences, McMaster University,
1200 Main Street West, Hamilton, ON, Canada L8N 3Z5Received 5 May 2011; received in revised form 21 September 2011; accepted 28 September 2011
Available online 8 October 2011Abstract The master regulatory gene Bmi1modulates key stem cell properties in neural precursor cells (NPCs), and has been
implicated in brain tumorigenesis. We previously identified a population of CD133+ brain tumor cells possessing stem cell prop-
erties, known as brain tumor initiating cells (BTICs). Here, we characterize the expression and role of Bmi1 in primary minimal-
ly cultured human glioblastoma (GBM) patient isolates in CD133+ and CD133− sorted populations. We find that Bmi1 expression
is increased in CD133− cells, and Bmi1 protein and transcript expression are highest during intermediate stages of differenti-
ation as CD133+ BTICs lose their CD133 expression. Furthermore, in vitro stem cell assays and Bmi1 knockdown show that Bmi1
contributes to self-renewal in CD133+ populations, but regulates proliferation and cell fate determination in CD133− popula-
tions. Finally, we test if our in vitro stem cell assays and Bmi1 expression in BTIC patient isolates are predictive of clinical out-
come for GBM patients. Bmi1 expression profiles show a marked elevation in the proneural GBM subtype, and stem cell
frequency as assessed by tumor sphere assays correlates with patient outcome.
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doi:10.1016/j.scr.2011.09.008Using the cell surface marker, CD133 (Yin et al., 1997; Yu
et al., 2002), we identified a subpopulation of cells from a va-
riety of human brain tumors, termed brain tumor initiating
cells (BTICs), which exhibit stem cell properties in vitro
142 C. Venugopal et al.(Singh et al., 2003; Reynolds and Weiss, 1992; Tropepe et al.,
1999) and in vivo (Singh et al., 2004; Wang et al., 2010). Sim-
ilar to neural precursor cells (NPCs), BTICs generate all neural
cell types through the process of differentiation, during which
CD133+ stem and early progenitor cells lose their CD133 ex-
pression, giving rise to late progenitors, and finally differenti-
ated progeny. Currently, there is a lack of definitive markers
defining NPC and BTIC early and late progenitors. However,
molecular markers which capture cells during the intermedi-
ate stages of differentiation, just as CD133 expression levels
begin to decline, may improve our understanding of signaling
pathways that promote BTIC cell fate determination.
The Bmi1 signaling pathway is not only required for execu-
tion of key stem cell programs in mammals, but is also consis-
tently dysregulated or overexpressed in numerous emerging
cancer stem cell populations (Cui et al., 2007; Lessard and
Sauvageau, 2003; Liu et al., 2006a; Mihic-Probst et al., 2007;
Song et al., 2006). The Bmi1 gene, first isolated as an onco-
gene in mouse lymphoma (van Lohuizen et al., 1991), was
also identified as a key regulator of hematopoietic (Lessard
and Sauvageau, 2003) and neural stem cell self-renewal (Fasano
et al., 2007, 2009; Molofsky et al., 2005). Bmi1 has been impli-
cated in the pathogenesis of brain tumors such as gliomas
(Bruggeman et al., 2007) and medulloblastoma (Leung et
al., 2004; Michael et al., 2008; Wiederschain et al.,
2007), and as an important epigenetic regulator of fate de-
termination in stem cell populations (Bracken et al., 2006;
Valk-Lingbeek et al., 2004). However, a targeted study of
the potential role of Bmi1 in further defining BTIC popula-
tions has yet to be performed.
Here, we use pre-existing BTIC assays and Bmi1 siRNA-
mediated knockdown to characterize the expression and stem
cell regulatory role of Bmi1 in primary minimally cultured
human glioblastoma (GBM) patient isolates prospectively sorted
for CD133. We show that Bmi1 governs key stem cell properties
in different cellular compartments: self-renewal in CD133+
stem and early progenitor cells, and proliferation, differentia-
tion and cell fate determination in CD133− progenitors. Our
work demonstrates that Bmi1 differentially regulates stem
cell function and cell identity in BTIC-enriched (CD133+) and
BTIC-depleted (CD133−) compartments of human glioblasto-
ma. Interestingly, in our minimally cultured GBM BTICs, we
find that Bmi1 mRNA expression level is significantly higher in
CD133− cell subpopulations, suggesting that Bmi1 may play a
previously uncharacterized role in CD133− late progenitor
populations, in addition to its known role in CD133+ stem cells
(Abdouh et al., 2009; Molofsky et al., 2003). While contributing
to stem cell self-renewal in CD133+ BTIC populations, Bmi1may
also play a role in regulating proliferation, differentiation and
tumor maintenance in CD133− populations. Furthermore, in
vitro stem cell assays are predictive of clinical outcome for
GBM patients, and Bmi1 expression in BTIC patient isolates
may contribute to current molecular classifications of GBM.
Results
Bmi1 expression is higher in the CD133− fractions of
human GBMs
We prospectively sorted CD133+ and CD133− cells from
primary human fetal brain (FB) specimens (n=34) andprimary human glioblastoma multiforme (GBM) (n=27,
Table 1). CD133 expression across all human BT samples
was 18.1±6.9%, and across human FB samples CD133 expres-
sion was 2.6±1.1%. We show that 12 representative primary
GBMs (Fig. 1A) and 5 normal primary FB samples (Supple-
mentary Fig. 1A), when assayed after minimal culture and
directly after formation of primary spheres, yielded a
CD133+ enriched fraction that housed significantly higher
self-renewal capacity in primary limiting dilution analyses
when compared to CD133− fractions (Pb0.0001 for both).
We offer these data to substantiate the claim that, in mini-
mally cultured primary human cells or BTIC patient isolates
(Singh et al., 2003, 2004; Uchida et al., 2000), CD133 expres-
sion reliably marks stem cell or early progenitor populations,
although this claim may not necessarily be extended to BTIC
cell lines or human glioma stem cells propagated in long-
term culture (Abdouh et al., 2009; Chen et al., 2010).
We hypothesized that since Bmi1 is essential for NPC self-
renewal (Fasano et al., 2007; Molofsky et al., 2003, 2005;
Bruggeman et al., 2005), it should be exclusively expressed
in CD133+ BTICs. We assayed mRNA and protein expression
in CD133-sorted populations from human GBMs. Interesting-
ly, we found that across all samples, Bmi1 mRNA (Fig. 1B)
and protein (Fig. 1C) expression levels are significantly
higher in CD133− populations compared to CD133+ popula-
tions. Similar trends were observed in human NPC popula-
tions (Supplementary Figs. 1B and C).
To investigate whether genes downstream of Bmi1 are
similarly activated in CD133− populations, we performed
RT-PCR and microarray experiments on both populations.
Bmi1 downstream effector gene p16 is repressed by Bmi1
and involved in proliferation control. RT-PCR experiments
show that p16 levels are decreased in CD133− populations
(Fig. 1D for GBMs and Supplementary Fig. 1D for NPCs).
Comparative microarray analysis also shows selective si-
lencing of p16 as well as other Bmi1 downstream targets
such as HoxD9, HoxD8, p14 and p27 in CD133− populations
(Fig. 1E).
Although Bmi1 expression and stem cell regulatory func-
tion have been well studied in CD133+ cells, the role of
Bmi1 in CD133− cells remains poorly characterized. We
therefore decided to investigate the potential role of Bmi1
in CD133− brain tumor cells.Bmi1 expression is highest during intermediate
stages of BTIC differentiation
Differentiation is a key stem cell property, during which
CD133+ stem and early progenitor cells lose their CD133 ex-
pression to give rise to late progenitors, and finally fully dif-
ferentiated neural cells (Singh et al., 2003). We performed
mRNA expression analysis of Bmi1 in CD133+ and CD133−
cells at days 0, 3 and 7 of differentiation (Fig. 2A). At day
3, Bmi1 mRNA expression peaks in the CD133+ population
and diminishes at day 7 to equal that of the CD133− popula-
tion. This led us to hypothesize that Bmi1 mRNA expression
may mark CD133+ progenitors as they lose CD133 expression
during differentiation.
In order to investigate this hypothesis, we quantified Bmi1
protein expression over the time course of differentiation, by
subjecting sorted CD133+ BTICs to differentiation assays
Table 1 Patient data and experimental use of BTIC isolates.
Specimen # Brain tumor ID Age/gender of donor patient Pathology CD133% in unsorted tumor Experimental use in figures
1 BT36 M/67 GBM 24.2 1a, 4b
2 BT47 M/59 GBM 12.2 1a, 1b, 1d, 4b, Supp Fig. 3a,b
3 BT62 M/54 GBM 16.3 1a, 2a, 2c, 4c
4 BT63 M/76 GBM 28.1 1a, 1d, 4b
5 BT75 M/69 GBM 22.1 1a, 4b
6 BT82 M/49 GBM 10.9 3c, 3d
7 BT89 M/57 GBM 24.3 1b, 2b, 2c
8 BT92 M/77 GBM 18.4 1b, 1e
9 BT104 M/74 GBM 13.2 1c, 2c
10 BT106 M/46 GBM 14.1 1a, 1c, 4b
11 BT111 F/34 GBM 10.8 1a
12 BT114 M/76 GBM 5.9 1d
13 BT119 M/63 GBM 24.9 1e
14 BT120 M/62 GBM 29.2 1a, 4b
15 BT121 M/51 GBM 15.8 1a, 3a, 3b, 3e, 3f
16 BT132 M/41 GBM 2.2 2a, 3a, 3b, 4b
17 BT147 M/82 GBM 19.2 1a, 4b
18 BT149 M/46 GBM 0.8 2a
19 BT154 F/59 GBM 10.7 1a, 4b
20 BT 54 M/47 GBM 17.0 1a, 1c, 4b
21 BT 132 M/41 GBM - 3a
22 BT 149 M/46 GBM 15.2 2b, 3c, 3d
23 BT210 F/75 GBM 16.8 4b, Supp Fig. 2
24 BT213 M/67 GBM - Supp Fig. 2, Supp Fig. 3a,b
25 BT237 M/51 GBM 11.2 3e, 3f
26 BT239 F/65 GBM 17.8 3c, 3d, Supp Fig. 2
27 BT305 M/48 GBM 10.5 4b, 4c
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et al., 1999) and flow cytometry on days 0, 3, 5, and 7. Results
for BTIC patient isolates (Fig. 2B) identified four cell popula-
tions that emerge sequentially over the time course of differ-
entiation. On day 0, 11% of CD133+ BTICs are Bmi1− and 87%
are Bmi1+; on day 3, only 5% of cells remain CD133+Bmi1+
and the majority of cells (94%) are CD133–Bmi1+. On day 5,
the most prominent population is CD133–Bmi1+, and by day
7, 99% of cells are CD133–Bmi1−.
To further characterize these four populations morpho-
logically, we performed immunofluorescence analysis on
CD133+ BTICs at days 0, 3, 5, and 7 of differentiation, stain-
ing for Bmi1, CD133 and markers of fully differentiated neu-
ronal and astrocytic lineages (TUJ1 and GFAP, respectively).
This staining (Fig. 2C, replicates shown in Supplementary
Fig. 2) showed that cellular morphology, combined with
marker expression over time, demonstrates the transition
of undifferentiated BTICs through progenitor stages to fully
differentiated progeny. Bmi1 expression marks intermediate
precursors during this transition from CD133+ BTICs to
CD133− differentiated cells.
We then evaluated the transcript levels of known regula-
tors and effectors of Bmi1 throughout differentiation. The
Notch pathway regulates self-renewal of Bmi1+ BTICs (Fan
et al., 2009), and p21 (Fasano et al., 2007) is a cell cycle reg-
ulator repressed by Bmi1 in NPCs. We show that throughout
differentiation of BTICs, p21 transcript levels vary inversely
with Bmi1 levels, whereas Notch1 and Bmi1 transcript levels
decrease concordantly (Supplementary Fig. 3).Bmi1 siRNA knockdown exerts multiple effects on
stem cell properties of CD133+ and CD133− brain
tumor cells
To determine a functional role for Bmi1 in our sorted cell
populations, we carried out knockdown studies on these
cells and subsequently performed in vitro stem cell assays
for self-renewal, proliferation and differentiation. We first
validated that siRNA targeted to Bmi1 decreased mRNA ex-
pression of Bmi1 and increased levels of downstream target
p16 (Supplementary Figs. 4A and B).
Limiting dilution analysis estimates the clonogenic stem
cell frequency of a whole cell population by quantifying sec-
ondary sphere formation, which correlates directly with
self-renewal capacity (Singh et al., 2003; Tropepe et al.,
1999; Singh et al., 2004; Bellows and Aubin, 1989). We
found that Bmi1 knockdown significantly reduced the num-
ber of secondary spheres, and thus self-renewal capacity,
in CD133+ BTICs (Fig. 3A, P=0.023). However, Bmi1 knock-
down had no significant effect on secondary sphere forma-
tion in the CD133− population (Fig. 3A, P=0.11).
Next, we chose to analyse proliferation on sorted knock-
down cells. These assays showed that Bmi1 knockdown re-
duced proliferative activity of both populations, especially
the CD133− population (Fig. 3B, P=0.001 for CD133− cells,
P=0.03 for CD133+ cells). Cell cycle analysis of BTICs showed
that Bmi1 knockdown reduced the number of cells found in S
phase (Figs. 3C and D), recapitulating Bmi1 knockdown ef-
fects in leukemic stem cells (Lessard and Sauvageau, 2003)
Figure 1 Bmi1 expression is higher in CD133− cells in human brain tumors. (A) In 12 representative primary GBMs (BTs 1–5, 10, 11,
14, 15, 17, 19, 20) assayed after minimal culture and directly after formation of primary spheres, CD133+ cells, when compared to
CD133− fractions, showed significantly higher secondary sphere formation in primary limiting dilution analyses (Pb0.0001) (B) Bmi1
mRNA expression levels are higher in the CD133− cells in human BTs (P=0.012, n=3, BTs 2, 7, 8). (C) Bmi1 protein levels are also
higher in the CD133− cells (P=0.0004 for BTs, n=3, BTs 9, 10 and 20). U2OS cell lysate served as positive control. Bottom panel
shows the immunoblot normalized to GAPDH as internal control. (D) mRNA expression levels of p16 are decreased in CD133− cells
(n=3 for BTs 2, 4, 12). (E) Treeview representation of Affymetrix expression data depicting known Bmi1 downstream target genes
that are silenced in the CD133− population (n=2 for BTs 8 and 13). ⁎Pb0.05, **Pb0.01.
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145Bmi1 marks intermediate precursors in brain tumorsand further corroborating the role of Bmi1 in regulation of
proliferation (Lessard and Sauvageau, 2003; Molofsky et
al., 2005; Bruggeman et al., 2005). These data show that
Bmi1 knockdown affects self-renewal in the CD133+ popula-
tion (as shown by decreased sphere number in Fig. 3A),
whereas maintenance of proliferation is affected mostly in
the CD133− compartment (as shown by decreased prolifera-
tion in Fig. 3B and significantly decreased number of CD133−
cells in S phase in Fig. 3D).
To assess the impact of Bmi1 on cell fate determination,
we plated Bmi1 knockdown cells for subsequent differentia-
tion and staining. Control siRNA treated CD133− cells were
fully differentiated with multiple processes after 5 days of
differentiation (Fig. 3E). However after Bmi1 knockdown,Figure 2 Bmi1 expression is highest during intermediate stages of
jected to differentiation assays (n=3 for BTs 3, 16 and 18), Bmi1 mRN
7, whereas, in CD133− cells, Bmi1 mRNA expression levels decrease
tative flow cytometry analysis of Bmi1 and CD133 protein expression
Throughout differentiation, four distinct cell populations (as describ
microscopic images of unsorted spheres (from representative sample
profile. Day 0: Undifferentiated spheres show central CD133 (red) an
arrows) and CD133+/Bmi1+ (yellow arrows) cell populations emerg
arrow); Day 7: Few cells retain Bmi1 expression (thick green arro
(red arrow, Day 7 left panel) and neuronal marker TUJ1 (red arrowsdifferentiation was partially blocked as indicated by spheri-
cal cells lacking mature processes (Fig. 3E, black arrows).
The restriction of neurogenic potential and default to a
glial fate reported by others (Fasano et al., 2009; Bruggeman
et al., 2007) was seen primarily with Bmi1 knockdown of the
CD133− cells (Fig. 3F), whereas CD133+ cells showed
completely blocked differentiation.Bmi1 is enriched in the proneural subtype of GBM and
tumor sphere assays correlate with patient outcome
We noted that throughout all experiments, Bmi1 expres-
sion levels are uniformly higher in brain tumor cell populationsBTIC differentiation. (A) In CD133+ cells from brain tumors sub-
A expression levels are increased at day 3 and decreased by day
d throughout differentiation (for day 3, *Pb0.05). (B) Represen-
in sorted CD133+ cells from human BT 7 (n=2 for BTs 7 and 22).
ed in text) were identified. Inset: isotype controls. (C) Confocal
, BT 3; n=3 for BTs 3, 7, 9) show their time course differentiation
d peripheral Bmi1 (green) staining ; Day 3: CD133+/Bmi1− (red
ed; Day 5: Only 50% of cells retain Bmi1 expression (thin green
w) whereas most now express mature astrocytic marker GFAP
, Day 7 right panel) respectively.
Figure 3 Bmi1 siRNA knockdown has differential effects on stem cell properties of CD133+ and CD133− cells. (A) Bmi1 siRNA con-
siderably decreased secondary sphere formation in CD133+ cells (P=0.023) but not in CD133− cells (P=0.11) (n=3 for BTs 15, 16
and 21). (B) Bmi1 knockdown decreased cell proliferation in both populations (n=2 for BTs 15 and 16), although the effect was
more marked in the CD133− population (P=0.001 for CD133− cells, compared to P=0.03 for CD133+ cells) (RFU=relative fluores-
cence units). (C) Cell cycle analysis showed that Bmi1 knockdown decreased the S phase in both CD133+ and CD133− populations,
(D) although the effect was more marked in CD133− populations (n=3 for BTs 6, 22, 26). (E) Control siRNA treated CD133− cells
were fully differentiated with multiple processes after 5 days of differentiation (n=2 for BTs 15 and 25; representative samples
shown from BT 15). However after Bmi1 knockdown, differentiation was partially blocked as indicated by spherical cells morpholog-
ically representative of dedifferentiation (black arrows). (F) Bmi1 knockdown decreased the number of cells expressing mature neu-
ronal markers (TUJ1, MAP2) in CD133− cells compared to control siRNA. ⁎Pb0.05, **Pb0.01, ***Pb0.001.
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tary Fig. 1). This observation is confirmed by reports of Bmi1
overexpression in brain tumors such as medulloblastomas
(Leung et al., 2004; Michael et al., 2008; Wiederschain et
al., 2007; Bracken et al., 2006), and the identification of a
Bmi1-driven gene signature through a mouse/human compar-
ative translational genomics approach which has beenvalidated in numerous human cancers (Glinsky et al., 2005).
Further reports have also suggested that Bmi1 confers radiore-
sistance to GBM CD133+ cells through preferential activation
of the DNA double-strand break response machinery, leading
to decreased survival (Facchino et al., 2010). Using the TCGA
GBM database (http://tcga-data.nci.nih.gov/tcga/
findArchives.htm), we analyzed Bmi1 and CD133 expression
147Bmi1 marks intermediate precursors in brain tumorsin 203 GBMs across the 4 GBM subgroups (Fig. 4A). These
data show a statistically significant enrichment of both
CD133 and Bmi1 in the proneural subgroup compared to
other subgroups. The proneural subgroup is associated
with younger age, secondary GBM presentation and a higher
expression of oligodendroglial and developmental genes
(such as PDGFRA, which is often expressed in the subventri-
cular zone where stem cells reside) (Verhaak et al., 2010).
The markedly increased expression of BTIC and stem/Figure 4 BTIC patient isolate stem cell assays correlate with patie
database (http://tcgadata.nci.nih.gov/tcga/findArchives.htm), sho
subgroup compared to the other GBM subtypes. (B) We analyzed 12
24-month period of documented clinical follow-up (BT 1, 2, 4, 5,
isolate sphere formation rates against months of survival. There is
mation rate and time to survival, indicating that as the numbe
(R2=0.723, Pb0.01). (C) 12 patient GBMs (BT 1, 2, 4, 5, 10, 14, 1
scored for high or low expression. Proneural GBMs identified by hig
pared to all other GBM subtypes. (D) Bmi1 (P=0.11) and CD133 (P=0
other GBM subtypes (n=5).progenitor markers such as CD133 and Bmi1 in the proneural
subtype of GBMs supports its origin from a transformed neu-
ral stem or progenitor cell.
To validate the application of in vitro stem cell assays to
patient tumors, we undertook statistical comparison of BTIC
patient isolate sphere formation rate (which approximates
stem cell frequency in a cell population) and patient survival.
We analyzed 12 GBM patients from our patient population who
had at least a 24-month period of documented clinical follow-nt outcome. (A) Expression analysis of Bmi1 using the TCGA GBM
ws a statistically significant enrichment of Bmi1 in the Proneural
GBM patients from our patient population who had at least a
10, 14, 16, 17, 19, 20, 23, 27), and plotted their BTIC patient
an 85% negative correlation between the secondary sphere for-
r of secondary spheres increases, time to survival decreases
6, 17, 19, 20, 23, 27) were stained with PDGFRA antibody and
h expression of PDGFRA show a lower self-renewal index com-
.13) expression is higher in proneural GBMs (n=5) compared to

























148 C. Venugopal et al.up, and plotted their BTIC patient isolate sphere formation
rates against months of survival (Fig. 4B). There is an 85% neg-
ative correlation between the secondary sphere formation
rate and time to survival, indicating that as the number of sec-
ondary spheres increases, time to survival decreases
(R2=0.723, Pb0.01). This correlation between BTIC sphere
formation rates and patient survival demonstrates that in
vitro stem cell assays reliably define stem cell frequency and
can be predictive of patient outcome, and may thus serve as
valid surrogates of BTIC xenograft tumorigenicity.
We also wanted to validate the feasibility of implement-
ing Bmi1 and CD133 expression studies to identify stem cell
populations in patient tumors. We performed immunohisto-
chemistry for antibodies against CD133, Bmi1 and PDGFRA
on tissue sections from the 12 GBM patients represented
in Fig. 4B (representative immunohistochemistry shown in
Supplementary Fig. 5). We chose PDGFRA as according to
TCGA analysis (Verhaak et al., 2010), its high-level expres-
sion should specifically correlate with the proneural sub-
type of GBMs, and would allow us to segregate proneural
GBMs from all other subtypes. Indeed, we found that
patients with high levels of PDGFRA expression tended to
be younger patients (see Table 3), often with secondary
GBMs, all of whom were alive at the end of the survival
analysis. Patient tumors with high levels of PDGFRATable 3 GBM patient data with Molecular subtype.









BT 1 67 Dead Other
BT 2 76 Dead Other
BT 3 34 Alive Proneural
BT 4 51 Alive Proneural
BT 5 69 Dead Other
BT 10 46 Alive Proneural
BT 11 59 Dead Other
BT 14 62 Dead Other
BT 15 81 Dead Other
BT 17 76 Dead Other
BT 19 59 Alive Proneural
BT 20 45 Alive Proneuralexpression (i.e. proneural GBMs) showed lower rates of sec-
ondary sphere formation compared to all other GBM sub-
types (Fig. 4C), showing that in these patients, a lower
rate of self-renewal correlates with survival. We then ana-
lyzed expression of Bmi1 and CD133 in proneural subtypes
(n=5) vs other GBM subtypes (n=5), and found that Bmi1
and CD133 expression are higher in the proneural GBMs
(Fig. 4D), corresponding with a likely stem cell origin as postu-
lated by Verhaak et al. (Verhaak et al., 2010). According to
TCGA analysis data, although proneural GBM patients are
younger at diagnosis and have a longer overall survival, they
respond to treatment poorly and have a relative survival disad-
vantage once treated with aggressive therapy. Proneural
GBMs may be particularly refractory to post-surgical chemo-
therapy and radiotherapy if their stem cell populations
evade these aggressive treatments, as suggested by the can-
cer stem cell hypothesis (Bao et al., 2006; Liu et al., 2006b;
McCord et al., 2009; Nakai et al., 2009). These data show
that Bmi1 and CD133 immunostaining combined with current
molecular subtyping may offer prognostic or diagnostic value
if applied to routine pathological examination in GBM patient
populations.Discussion
We have analyzed Bmi1 expression and function in human
GBM patient isolates prospectively sorted for CD133, rather
than in whole spheres, which are heterogeneous stem cell
colonies that contain a mixture of stem, progenitor and dif-
ferentiated cells. We called our experimental model system
“BTIC patient isolates” to emphasize the fact that these
cells are not cell lines, but rather minimally cultured under
conditions to select for stem cell populations. BTICs are
assayed immediately after primary sphere formation, and
grown briefly in human NPC media with LIF. Under these
conditions, we find that CD133 reliably marks stem or early
progenitor populations (Singh et al., 2003, 2004; Wang et
al., 2010; Uchida et al., 2000) (Fig. 1A), although this finding
may not pertain to human BTICs propagated in long-term
culture (Abdouh et al., 2009; Chen et al., 2010).
Bmi1 is known to act in a concentration-dependent man-
ner to control a delicate balance between self-renewal and
differentiation (Cui et al., 2006). We found that Bmi1 ex-
pression is highest during intermediate stages of BTIC differ-
entiation, when CD133+ progenitors transition to CD133−
cells prior to acquisition of a fully differentiated state.
These results are corroborated by functional data obtained
from Bmi1-GFP knock-in mice (Hosen et al., 2007). It is likely
that Bmi1 partners with other transcription factors in the
temporal control of self-renewal and differentiation. For ex-
ample, Bmi1 and Mel18 (Ishida et al., 1993) are highly ho-
mologous constituents of the PRC1 complex, and studies
have shown that Mel18 negatively regulates Bmi1 expression
(Guo et al., 2007). It has also been observed that Bmi1 ex-
pression is upregulated in the earlier stages of differentia-
tion, while Mel18 levels increase in the later stages of
differentiation (Lessard and Sauvageau, 2003; Hosen et al.,
2007). It is possible that when the CD133− cells fully differ-
entiate, Mel18 levels increase, thereby decreasing Bmi1
levels to give rise to CD133− Bmi1− fully differentiated
cells.
149Bmi1 marks intermediate precursors in brain tumorsBmi1 activity could also be modulated by the presence of
alternatively spliced variants during self renewal and differ-
entiation, hinting at an additional level of regulatory com-
plexity in BTICs. Such is the case for Oct4, as Oct4 splice
variants are differentially expressed in human pluripotent
and nonpluripotent cells: Oct 4A in stem cells and Oct4B in
differentiated cells (Atlasi et al., 2008). Sorting of brain
tumor cells for CD133 allowed us to make the novel observa-
tion that Bmi1 governs key stem cell properties in different
cellular compartments. Bmi1 regulates self-renewal in
CD133+ stem and early progenitor cells, and regulates prolif-
eration, differentiation and cell fate determination in
CD133− progenitors.
Bmi1 belongs to a family of polycomb group (PcG) pro-
teins which together form multimeric complexes responsible
for gene silencing via chromatin modification. Bmi1, in par-
ticular, belongs to the PRC1 complex, which is more func-
tionally redundant through paralogous genes, but has been
reported to be critical in cancer development (Margueron
and Reinberg, 2011; Simon and Kingston, 2009). The current
mechanistic theory of gene silencing through chromatin
compaction follows two steps. First, PRC2 proteins E(Z),
ESC, and SU(Z)12 form the core responsible for the initiation
of gene repression. Second, the PRC1 complex, which in-
cludes PCGF, Ring1, PHC and CHX components, is recruited
and causes a covalent modification leading to chromatin
compaction (Sauvageau and Sauvageau, 2008). In the cancer
stem cell hypothesis, it is suggested that a sub-population of
cells have stem cell characteristics that lead to the genera-
tion of a heterogeneous tumor. Stem cell pluripotency re-
quires that lineage specific programs are repressed, and
this has been demonstrated to be partly due to PcG regula-
tion. In BTICs, PcG proteins may drive the cells towards a
stem cell phenotype. Thus, in early BTIC progenitors, it ap-
pears that PcG proteins, such as Bmi1, may be responsible
to maintain BTICs in a stem cell state primed for differenti-
ation (Sauvageau and Sauvageau, 2008). As the stem cells/
early progenitors begin to specify into late progenitors,
PcGs appear to function to restrict certain lineage programs
for cell fate determination.
Cellular identity is maintained through chromatin modi-
fications during cell division. The Polycomb group proteins,
and specifically Bmi1, have been shown to guide cell-fate
decisions in a number of normal somatic and cancer stem
cell populations. Initial work in hematopoietic (HSC) (Park
et al., 2003), leukemic (LSC) (Lessard and Sauvageau,
2003), and neural (NSC) (Molofsky et al., 2003) stem cells
identified Bmi1 as a regulator of the key stem cell property,
self-renewal. Paired daughter cell assays in CD34−c-
Kit+Sca-1+lineage marker- HSCs have demonstrated overex-
pression of Bmi1 to enhance in vitro symmetrical cell divi-
sion of HSCs (Iwama et al., 2004). Our work demonstrates
for the first time that Bmi1 differentially regulates cell
identity in BTIC-enriched (CD133+) and BTIC-depleted
(CD133−) compartments of glioblastoma. Although our
work does not explore the mechanism by which Bmi1 main-
tains symmetric and asymmetric cell division in BTICs, it
may be hypothesized that it regulates asymmetric division
in CD133+ cells and then symmetrically maintains CD133−
cells.
The critical role of Bmi1 in tumorigenesis has prompted
investigations into genes upstream of this proto-oncogene.Several candidate genes have been reported to be upstream
of Bmi1 in various cancer models. In neuroblastoma, MYCN
and E2F-1 appears to be regulating Bmi1 expression (Ochiai
et al., 2010; Nowak et al., 2006), whereas in leukemia, this
role appears to be played by SALL4 (Yang et al., 2007). In
medulloblastoma, it appears that sonic hedgehog (Shh)
may have a direct regulatory function, and Twist1 may be
an important regulator upstream of Bmi1 (Wang et al.,
2011). In GBMs however, several reports have shown the im-
portance of miRNA-128 as a direct regulator of Bmi1 through
binding to a 3′-untranslated region of Bmi1 mRNA. Overex-
pression of miRNA-128 resulted in a decrease in Bmi1 expres-
sion, suggesting that miRNA-128 may represent a potential
therapeutic target for GBM BTICs (Cui et al., 2010; Godlewski
et al., 2008).
Finally, we sought to test if our in vitro stem cell assays
and marker expression in BTIC patient isolates were clinically
relevant for GBM patients. The markedly increased expres-
sion of Bmi1 in the proneural GBM subtype reveals the poten-
tial for stem cell markers to further elucidate current
molecular GBM classifications. We also show that our markers
could feasibly be assessed by immunohistochemistry in pa-
tient tumors, and further work assessing the functional role
of these presumed BTIC populations will offer validation of
their future clinical utility. While xenograft models currently
represent the gold standard for BTIC definition (Singh et al.,
2004; Bonnet and Dick, 1997), we offer compelling evidence
that sphere formation in early passage BTIC patient isolates
is, in fact, a surrogate for tumorigenicity in xenografts, in
that higher BTIC sphere formation rate correlates strongly
with shorter patient survival. Together with other work link-
ing high sphere formation rates to poor patient outcome
(Kong et al., 2010; Panosyan et al., 2010; Yuan et al., 2004;
Laks et al., 2009), these data may serve to validate sphere
formation as a viable surrogate for the xenograft model in de-
termining BTIC potency and frequency. Further diagnostic
and prognostic information can be extracted from these out-
come analyses; for example, if the line of least square linear
fit shown in Fig. 4B is intersected at 15 months' survival (the
mean survival time of all patients with GBM who receive
gold standard therapy of surgery, temozolomide chemother-
apy and radiation (Stupp et al., 2005)), an intercept of 48.4
spheres per 2000 cells is generated, which could be validated
in larger GBM patient cohorts as a prognostic indicator (i.e.,
b48.4 spheres predicts longer survival, N48.4 spheres pre-
dicts shorter survival).
In multiple cancer models, Bmi1 is an oncoprotein pre-
requisite for transformation, metastatic migration, and
maintenance of malignancy (Liu et al., 2006a; Bruggeman
et al., 2007; Michael et al., 2008; Glinsky et al., 2005;
Dovey et al., 2008). In the context of brain tumorigenesis,
our data suggest that Bmi1 may regulate tumor initiation in
CD133+ BTICs and tumor maintenance in CD133− prolifera-
tive progenitors. However, whether Bmi1 overexpression in
human NPCs in vivo is necessary and sufficient for brain
tumor generation remains largely unexplored (Fasano et
al., 2009; He et al., 2009). Conversely, the effect of Bmi1
knockdown in human BTICs on in vivo brain tumorigenesis
has not yet been fully elucidated (Abdouh et al., 2009). It
will be important to investigate the role of Bmi1 in stem
cell maintenance as it applies to in vivo models of brain
tumorigenesis.
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Primary cell and sphere culture
We have called our experimental model system “BTIC pa-
tient isolates” to emphasize the fact that these cells are
only minimally cultured (24 hours to b1 week) under condi-
tions, which select for stem cell populations. These BTIC pa-
tient isolates are not cell lines, and small cell numbers have
necessitated experimental repetition in multiple primary
patient isolates to attain statistical significance. Patient iso-
lates are described in Table 1. Human brain tumor (BT) and
whole 13- or 14-week fetal brain (FB) samples were obtained
from consenting patients, as approved by the Hamilton
Health Sciences/McMaster Health Sciences Research Ethics
Board. As previously published (Singh et al., 2003, 2004),
samples were dissociated in artificial cerebrospinal fluid
containing 0.2 Wunisch Unit/mL Liberase Blendzyme® 3
(Roche), and placed in a rocking incubator at 37 °C for
15 minutes. The dissociated tissue was then filtered through
a 70 μm cell strainer and collected by centrifugation at
1500 rpm for 3 minutes. Tumor cells were resuspended in
Tumor Sphere Medium (TSM) consisting of a chemically de-
fined serum-free neural stem cell medium (Singh et al.,
2003; Singh et al., 2004), human recombinant EGF (20 ng/
mL; Sigma), bFGF (20 ng/mL; Invitrogen), LIF (10 ng/mL;
Chemicon), Neural Survival Factor (NSF) (1×; Clonetics), N-
acetylcysteine (60 μg/mL; Sigma) and antibiotic antimycotic
solution (Wisent). Red blood cells were removed using am-
monium chloride (STEMCELL Technologies). All experiments
were performed following minimal culture (b1 week). Via-
bility was measured at N80% for inclusion in these experi-
ments, and was ascertained by 7AAD staining by flow
cytometry, or trypan blue dye exclusion.
Magnetic cell sorting and flow cytometry analysis
Primary spheres were dissociated with Liberase Blendzyme®
3 to single cell suspension. CD133+ cells were purified using
magnetic bead cell sorting (STEMCELL Technologies) as pre-
viously published (Singh et al., 2003; Singh et al., 2004) or
flow cytometric sorting. The percentage expression of
unsorted cells, CD133+ selected cells and the CD133-
negative fraction was determined by flow cytometry (FACS-
Calibur, BD Biosciences or MoFlo XDP, Beckman Coulter)
using APC-labeled anti-CD133 antibodies (Miltenyi Biotec).
The purity of CD133+ cell fractions from brain tumors was
85±3.4%, and the CD133− cell fraction purity was 99.5±
0.3%. For human NPCs, the purity of CD133+ cells was 89±
4.6%, and CD133− cell fraction purity was 99.3±0.4%. The
appropriate isotype control served as the negative control
for every experiment.
Limiting dilution assay (LDA)
After primary sphere formation was noted, spheres were dis-
sociated to single cells and replated in 0.2 mL TSM as previ-
ously published (Singh et al., 2003; Singh et al., 2004).
Briefly, neurospheres were treated with Liberase Blend-
zyme® 3 and plated at clonal density in 96-well microwell
plates in 0.2 mL volumes of TSM. Final cell dilutions rangedfrom 200 cells per well to 1 cell per well in 0.2 mL volumes.
Cultures were fed 0.025 mL of TSM every 2 days until day 7,
when the number of secondary spheres formed per 2000
cells was counted and represented graphically in Fig. 1a.
To rule out the possibility that primary spheres represented
cell aggregates, we plated bulk GBM cultures at 12 hours
(n=4) at single cell density, and through primary LDA,
found that single cells possess sphere forming capacity. For
primary LDA, on day 7, the percentage of wells not contain-
ing spheres for each cell plating density (F0) is calculated
and plotted against the number of cells per well (x). The
number of cells required to form at least one tumor sphere
in every well is determined from the point at which the
line crosses the 0.37 level (F0=e−x) (Tropepe et al., 1999;
Bellows and Aubin, 1989).
Cell proliferation assay
Cell proliferation assay was performed on days 0, 3, 5 and 7
using CyQuant Cell Proliferation Kit (Invitrogen) as per man-
ufacturer's instructions. Cells were plated in 96 well micro-
well plates in 0.1 mL TSM with 20% FBS at the density of
100 cells/well. The media was changed every other day.
The plates were read with FLUOstar Omega fluorescence
Microplate reader (BMG LABTECH) at λEx=485, λEm=525.
Bmi1 siRNA treatment
Sorted CD133+ and CD133− cells from brain tumors were im-
mediately treated with human Bmi1 siRNA, which is a pool of
3 target specific siRNAs (Santa Cruz Biotechnology). Follow-
ing treatment, Bmi1 mRNA expression was measured by
real-time PCR to determine the efficiency of knockdown.
Cells treatedwith scrambled siRNA (Santa Cruz Biotechnology)
were used as controls. Knockdown effects were validated by
the use of Bmi1 shRNA constructs and three other independent
Bmi1 siRNA (Santa Cruz Biotechnology). Secondary sphere for-
mation, proliferation assay, cell cycle analysis, and differenti-
ation assays were performed prior to and after Bmi1 siRNA
treatment.
Quantitative cell cycle experiments
Cell cycle experiments were performed using BrdU-FITC flow
kit (BD Pharmingen). Sorted human BT cells were incubated
with 10 μM BrdU for 1 hour after treatment with control or
Bmi1 siRNA. Then, cells were fixed and co-stained with 7-
AAD for DNA content.
Differentiation assay and immunofluoresence staining
Cell fixation and immunofluorescence staining were per-
formed as described previously (Singh et al., 2003, 2004).
For the staining of undifferentiated spheres, unsorted
spheres were plated onto glass coverslips coated with 1:10
diluted Matrigel (BD Biosciences) in TSM without FBS. Four
hours later, the spheres were fixed and permeabilized with
Cytoperm/Cytofix buffer kit (BD Biosciences). For staining
of differentiated cells, unsorted spheres were cultured in
TSM supplemented with 20% FBS which was replaced every
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7 days after differentiation with the appropriate antibodies.
All primary antibodies were incubated overnight at 4 °C, in
the following the dilutions: CD133/1 (Miltenyi Biotec)
1:200, Bmi1 (Upstate) 1:100, TUJ-1 (Sigma) 1:1000, Nestin
(BD bioscience) 1:100 and GFAP (DAKO) 1:100. All secondary
antibodies (conjugated to Alexa 488 or Alexa 647) were di-
luted 1:1000. After staining with Hoechst 33342 (Molecule
Probes), slides were coverslipped using Fluorescence Mount-
ing Medium (DAKO). Images were taken using Olympus spin-
ning disk confocal microscope.Real-time PCR
Total RNA was isolated using Qiagen RNeasy Micro Kit. cDNA
was synthesized by qScript cDNA supermix followed by real-
time PCR using iQSYBR Green Kit (Quanta) with GAPDH as an
internal control. Samples were quantified using Opticon
software. Data were presented as the ratio of the gene of in-
terest to GAPDH. No changes were noted with 28srRNA as a
control, validating that gene expression was not affected
by hypoxia (Zhong and Simons, 1999). Primer sequences
are provided in Table 2. To further confirm our results
obtained in Fig. 1B, real-time RT–PCR was repeated with
TaqMan universal PCR Master Mix (Applied Biosystems), and
the Bmi1 Taqman Gene Expression Kit.Immunohistochemistry
Briefly, 5 μm sections were cut from paraffin-embedded pa-
tient GBMs and mounted on positively charged microscope
slides. The sections were baked overnight at 60 °C, dewaxed
in xylene, and hydrated through immersion in decreasing
concentrations of ethanol in distilled water. The tissue sec-
tions were heat treated for the purpose of antigen retrieval
and blocked for endogenous biotin and peroxidase. Tissue
sections were stained using antibodies against CD133
(Miltenyi Biotec), Bmi1 (R&D systems) and PDGFRA (Cell
signaling), and incubated overnight at 4 °C, according to
previously published protocols (Singh et al., 2003, 2004).
10 high-power (400×) fields were blindly assessed by two
authors (JP, BM) for each of our 12 patients. Average inten-
sity of staining was measured using a 0 (negative), 1 (low),
2 (intermediate), 3 (high) scale. Average percent of positive
staining was determined by counting positive stains in 100
cells per field. Proneural subtypes were classified according
to staining intensity as having an average score N1.8 and all
other tumors with intensity scores b1.5 were identified as
“other subtypes”.Statistical analysis
All quantitative data presented are the mean±sem. Samples
used and the respective n values are listed in the figure
legends. The level of significance was determined by
Student's two-tailed t-test or ANOVA with α=0.05 (GraphPad
Software).
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